Skip to main content

Allogeneic Hematopoietic Stem Cell Transplantation

1
Pipeline Programs
3
Companies
3
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

Takeda
ENTYVIOApproved
vedolizumab
Takeda
Integrin Receptor Antagonist [EPC]injection2014
100M Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
ENTYVIO(Vedolizumab)PHASE_2Monoclonal Antibody1 trial
Active Trials
NCT02993783Terminated17Est. May 2018
Eppendorf
EppendorfGermany - Hamburg
1 program
Humor therapyN/A1 trial
Active Trials
NCT03593161Unknown126Est. Sep 2019
Seres Therapeutics
Seres TherapeuticsCAMBRIDGE, MA
1 program
Vancomycin Pre-TreatmentPHASE_11 trial
Active Trials
NCT04995653Completed60Est. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaVedolizumab
Seres TherapeuticsVancomycin Pre-Treatment
EppendorfHumor therapy

Clinical Trials (3)

Total enrollment: 203 patients across 3 trials

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Start: Apr 2017Est. completion: May 201817 patients
Phase 2Terminated
NCT04995653Seres TherapeuticsVancomycin Pre-Treatment

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

Start: Nov 2021Est. completion: Jul 202460 patients
Phase 1Completed

Humor Therapy and Distress After Allogeneic Stem Cell Transplantation

Start: May 2018Est. completion: Sep 2019126 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.